- Start
- Therapeutic Targeting of RAS Mutant Cancers
Therapeutic Targeting of RAS Mutant Cancers
Angebote / Angebote:
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations.
Folgt in ca. 15 Arbeitstagen